Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Solanezumab multiple-dose safety in Japanese AD patients
NCT00749216Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- Sep 2008
- Primary completion
- Jul 2009
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of solanezumab in Alzheimer's disease (AD), sponsored by Eli Lilly and Company. Started Sep 2008; status: completed.
02
Drugs
solanezumab
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT00749216.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00749216.